Progress of proton pump inhibitors using in cancer patients

doi:10.12092/j.issn.1009-2501.2018.10.015

Abstract

Abstract:

Proton pump inhibitors (PPIs) are a class of drugs that inhibit gastric acid secretion. They are used in the treatment of acute and chronic digestive diseases. They are also commonly used in chemical therapy, radiation therapy, stress ulcers and prophylactic administration of steroids. In clinical research, it is found that most of the preventive administrations of PPIs are unreasonable. This article reviews the clinical trials and adverse reactions of PPIs in cancer patients, providing a reference for rational use of PPIs.

Key words: proton pump inhibitors, cancer, chemotherapy, steroids, drug interactions

CLC Number:

HUANG Qiong, DU Jie, CHENG Shuqiao, GONG Zhicheng. Progress of proton pump inhibitors using in cancer patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1179-1187.

References

［1］Lodato F, Poluzzi E, Raschi E, et al. Appropriateness of proton pump inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy［J］. Eur J Int Med, 2016, 30: 31-36.
［2］Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications［J］. Am J Gastroenterol, 2009, 104(3): 728-738.
［3］卢宏丽, 卢宏霞. 山西省某肿瘤医院住院患者质子泵抑制剂用药分析.［J］. 中国药物与临床, 2017, 17(6): 905-906.
［4］Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know［J］. Therap Adv Gastroenterol, 2012, 5(4): 219-232.
［5］Jacobson BC, Ferris TG, Shea TL, et al. Who is using chronic acid suppression therapy and why［J］? Am J Gastroenterol, 2003, 98(1): 51-58.
［6］Smelick GsH. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development ［J］. Mol Pharm, 2013, 11(10): 4055-4062.
［7］Sartori S, Nielsen I, Maestri A, et al. Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy ［J］. Oncology, 1991, 48(5): 356-361.
［8］Gorschluter M, Schmitz V, Mey U, et al. Endoscopy in patients with acute leukaemia after intensive chemotherapy［J］. Leuk Res, 2008, 32(10): 1510-1517.
［9］Numico G, Fusco V, Franco P, et al. Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use［J］. Crit Rev Oncol Hematol, 2017, 111: 144-151.
［10］Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up［J］. Ann Oncol, 2015, 26 Suppl 5: v139-v151.
［11］Mavligit GM, Faintuch J, Levin B, et al. Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue［J］. Gastroenterology, 1987, 92(3): 566-569.
［12］Aggarwal SK, San AJ, Sokhansanj A, et al. Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation［J］. Anticancer Drugs, 1994, 5(2): 177-193.
［13］Contu A, Marenco G, Pani P, et al. Preventive role of pirenzepine in gastric damage during cytostatic therapy. A controlled randomized double-blind study with placebo［J］. Minerva Dietol Gastroenterol, 1989, 35(4): 269-272.
［14］Mori K, Tominaga K, Yokoyama K, et al. Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine［J］. J Cancer Res Clin Oncol, 1995, 121(6): 367-370.
［15］Polloni A, Marchi S, Martire A, et al. Pirenzepine versus ranitidine in gastroprotection during antiblastic chemotherapy: a double-blind study［J］. Chemioterapia, 1986, 5(6): 420-423.
［16］Sartori S, Trevisani L, Nielsen I, et al. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study［J］. Cancer, 1996, 78(7): 1477-1482.
［17］Sartori S, Trevisani L, Nielsen I, et al. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury［J］. J Clin Oncol, 2000, 18(3): 463-467.
［18］Steer CB, Harper PG. Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors［J］. Eur J Gastroenterol Hepatol, 2002, 14 Suppl 1: S17-S21.
［19］翟蒙蒙, 李志刚, 沈杰, 等. 质子泵抑制剂对进展期胃癌化疗方案临床疗效的影响［J］. 中国临床药理学与治疗学, 2017, 8(22): 933-936.
［20］Bianchi PG, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients［J］. Am J Gastroenterol, 1997, 92(4): 663-667.
［21］Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions［J］. J Rheumatol Suppl, 1991, 28: 11-14.
［22］Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications［J］. Am J Gastroenterol, 2009, 104(3): 728-738.
［23］Borras JM, Lievens Y, Barton M, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis［J］. Radiother Oncol, 2016, 119(1): 5-11.
［24］Franco P, Zeverino M, Migliaccio F, et al. Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series［J］. J Cancer Res Clin Oncol, 2013, 139(11): 1927-1936.
［25］Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event?［J］ Tumori, 2006, 92(2): 87-91.
［26］Steer CB, Harper PG. Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors［J］. Eur J Gastroenterol Hepatol, 2002, 14 Suppl 1: S17-S21.
［27］ Berkey FJ. Managing the adverse effects of radiation therapy［J］. Am Fam Physician, 2010, 82(4): 381-388, 394.
［28］Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract［J］. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1213-1236.
［29］Biju PG, Gubrij I, Garg S, et al. Radiation lethality potentiation in total body irradiated mice by a commonly prescribed proton pump inhibitor, Pantoprazole sodium［J］. Int J Radiat Biol, 2014, 90(7): 554-559.
［30］Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo［J］. Biochem Pharmacol, 2004, 68(11): 2117-2127.
［31］Su Q, Wang D, Yuan B, et al. Effects of proton pump inhibitors on lung cancer precise radiotherapy-induced radiation pneumonitis［J］. Cell Biochem Biophys, 2014, 70(2): 1113-1117.
［32］Welsh C, Kasirer MY, Pan J, et al. Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition ［J］. Am J Physiol Gastrointest Liver Physiol, 2014, 307(3): G390-G396.
［33］Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study［J］. Arch Intern Med, 2007, 167(9): 950-955.
［34］Eddleston JM, Pearson RC, Holland J, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo［J］. Crit Care Med, 1994, 22(12): 1949-1954.
［35］Krag M, Perner A, Moller MH. Stress ulcer prophylaxis in the intensive care unit［J］. Curr Opin Crit Care, 2016, 22(2): 186-190.
［36］Krag M, Perner A, Wetterslev J, et al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients［J］. Intensive Care Med, 2015, 41(5): 833-845.
［37］Plummer MP, Blaser AR, Deane AM. Stress ulceration: prevalence, pathology and association with adverse outcomes［J］. Crit Care, 2014, 18(2): 213.
［38］Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group［J］. N Engl J Med, 1994, 330(6): 377-381.
［39］Marik PE, Vasu T, Hirani A, et al. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis［J］. Crit Care Med, 2010, 38(11): 2222-2228.
［40］Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis［J］. World J Crit Care Med, 2016, 5(1): 57-64.
［41］Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis［J］. Crit Care Med, 2013, 41(3): 693-705.
［42］Maclaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit［J］. JAMA Intern Med, 2014, 174(4): 564-574.
［43］Numico G, Russi EG, Vitiello R, et al. Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule［J］. Int J Radiat Oncol Biol Phys, 2006, 66(3): 731-737.
［44］Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009［J］. Support Care Cancer, 2011, 19 Suppl 1: S5-S14.
［45］Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia--pathophysiology and management［J］. J Gastroenterol, 2013, 48(5): 574-594.
［46］Luo JC, Chang FY, Chen TS, et al. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy［J］. Br J Clin Pharmacol, 2009, 68(2): 252-259.
［47］Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy ［J］. J Intern Med, 1994, 236(6): 619-632.
［48］Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis［J］. BMJ Open, 2014, 4(5): e4587.
［49］Jones MG, Tsega S, Cho HJ. Inappropriate prescription of proton pump inhibitors in the setting of steroid use: a teachable moment ［J］. JAMA Intern Med, 2016, 176(5): 594-595.
［50］Martinek J, Hlavova K, Zavada F, et al. "A surviving myth"--corticosteroids are still considered ulcerogenic by a majority of physicians［J］. Scand J Gastroenterol, 2010, 45(10): 1156-1161.
［51］Guslandi M. Steroid ulcers: Any news ［J］? World J Gastrointest Pharmacol Ther, 2013, 4(3): 39-40.
［52］Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis［J］. Am J Gastroenterol, 2012, 107(7): 1011-1019.
［53］Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea ［J］? J Hosp Infect, 2008, 70(1): 1-6.
［54］Taur Y, Pamer EG. Microbiome mediation of infections in the cancer setting［J］. Genome Med, 2016, 8(1): 40.
［55］Mccaleb RV, Gandhi AS, Clark SM, et al. Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center ［J］. Ann Pharmacother, 2016, 50(7): 541-547.
［56］Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis［J］. CMAJ, 2011, 183(3): 310-319.
［57］Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis ［J］. Gut, 2014, 63(4): 552-558.
［58］Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis［J］. Osteoporos Int, 2016, 27(1): 339-347.
［59］Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies［J］. Ren Fail, 2015, 37(7): 1237-1241.
［60］Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease［J］. JAMA Intern Med, 2016, 176(2): 238-246.
［61］Linder L, Tamboue C, Clements JN. Drug-induced vitamin B12 deficiency: a focus on proton pump inhibitors and histamine-2 antagonists ［J］. J Pharm Pract, 2017, 30(6): 639-642.
［62］Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome［J］. JAMA, 2009, 301(9): 937-944.
［63］Melloni C, Washam JB, Jones WS, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review［J］. Circ Cardiovasc Qual Outcome, 2015, 8(1): 47-55.
［64］Kuipers EJ. Proton pump inhibitors and gastric neoplasia［J］. Gut, 2006, 55(9): 1217-1221.
［65］Cheung KS, Chan EW, Wong A, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study［J］. Gut, 2018, 67(1): 28-35.
［66］Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions［J］. Cochrane Database Syst Rev, 2014(12): D10623.
［67］Taur Y, Pamer EG. Microbiome mediation of infections in the cancer setting［J］. Genome Med, 2016, 8(1): 40.
［68］Tran KT, Mcmenamin UC, Hicks B, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies［J］. Aliment Pharmacol Ther, 2018, 48(1): 55-64.
［69］Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors［J］. Clin Pharmacokinet, 2010, 49(8): 509-533.
［70］Conde-Estevez D. Targeted cancer therapy: interactions with other medicines［J］. Clin Transl Oncol, 2017, 19(1): 21-30.
［71］Ha VH, Ngo M, Chu MP, et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer［J］? J Oncol Pharm Pract, 2015, 21(3): 194-200.
［72］Chu MP, Ghosh S, Chambers CR, et al. Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer［J］. Clin Lung Cancer, 2015, 16(1): 33-39.
［73］Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients ［J］. Clin Colorectal Cancer, 2016, 15(3): 257-263.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[3]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[4]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[5]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[6]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[7]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[8]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[9]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[10]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[11]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[12]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[13]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[14]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[15]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.